Department of Laboratory Medicine, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH.
Am J Clin Pathol. 2019 Feb 4;151(3):337-343. doi: 10.1093/ajcp/aqy144.
To evaluate the clinical utility of immune receptor translocation-associated protein 1 (IRTA1) and myeloid nuclear differentiation antigen (MNDA) expression in the diagnosis and classification of marginal zone lymphomas (MZLs).
IRTA1 was examined using a novel RNA in situ hybridization assay and MNDA expression determined by immunohistochemistry in 127 small B-cell neoplasms, including 80 cases of MZL.
IRTA1 expression was detected in 31 (42%) of 74 MZLs vs one (2%) of 43 other small B-cell neoplasms (P < .001). MNDA staining was positive in 51 (64%) of 79 MZLs vs 21 (45%) of 46 non-MZLs (P = .06). MNDA expression was particularly uncommon in follicular lymphoma (3/14, 21%; P = .003 vs MZL). There was no association between MNDA and IRTA1 expression and the presence of monocytoid cytology. IRTA1 expression was less frequent in cases with a diffuse growth pattern.
IRTA1 and MNDA are useful markers in the differential diagnosis of MZLs.
评估免疫受体易位相关蛋白 1（IRTA1）和髓样核分化抗原（MNDA）表达在边缘区淋巴瘤（MZL）诊断和分类中的临床应用价值。
采用新型 RNA 原位杂交检测法检测 IRTA1，免疫组织化学法检测 MNDA 在 127 例小 B 细胞肿瘤中的表达，其中包括 80 例 MZL。
IRTA1 在 74 例 MZL 中有 31 例（42%）表达，而在 43 例其他小 B 细胞肿瘤中有 1 例（2%）表达（P <.001）。MNDA 在 79 例 MZL 中有 51 例（64%）表达，在 46 例非 MZL 中有 21 例（45%）表达（P =.06）。MNDA 在滤泡性淋巴瘤中表达特别少见（14 例中 3 例，21%；P =.003 与 MZL 相比）。MNDA 和 IRTA1 表达与单核细胞样细胞学的存在之间无相关性。弥漫性生长模式的病例中 IRTA1 表达频率较低。
IRTA1 和 MNDA 是 MZL 鉴别诊断中的有用标志物。
